Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics

AIDS. 2002 Oct 18;16(15):2081-3. doi: 10.1097/00002030-200210180-00015.

Abstract

Lopinavir/ritonavir was administered to 35 HIV-infected patients after therapeutic failure with other protease inhibitors. The pharmacokinetics (trough concentrations) and baseline viral genotype were determined, together with the immunovirological outcome. The 22 responders had significantly higher mean lopinavir concentrations and lower baseline numbers of mutations. On multivariate analysis, a lopinavir concentration of 5.7 microg/ml or greater was an independent predictor of viral suppression over a 9-month follow-up period.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD4 Lymphocyte Count
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV Protease / genetics
  • HIV Protease Inhibitors / pharmacokinetics*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1 / physiology
  • Humans
  • Lopinavir
  • Male
  • Mutation
  • Pyrimidinones / pharmacokinetics*
  • Pyrimidinones / therapeutic use
  • Ritonavir / pharmacokinetics*
  • Ritonavir / therapeutic use
  • Salvage Therapy*
  • Treatment Outcome
  • Viral Load

Substances

  • HIV Protease Inhibitors
  • Pyrimidinones
  • Lopinavir
  • HIV Protease
  • Ritonavir